[en] Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer's disease and to better understand the pathophysiological processes of disease progression. Preclinical Alzheimer's disease EEG changes would be non-invasive and cheap screening tools and could also help to predict future progression to clinical Alzheimer's disease. However, the impact of amyloid-beta deposition and neurodegeneration on EEG biomarkers needs to be elucidated. We included participants from the INSIGHT-preAD cohort, which is an ongoing single-centre multimodal observational study that was designed to identify risk factors and markers of progression to clinical Alzheimer's disease in 318 cognitively normal individuals aged 70-85 years with a subjective memory complaint. We divided the subjects into four groups, according to their amyloid status (based on 18F-florbetapir PET) and neurodegeneration status (evidenced by 18F-fluorodeoxyglucose PET brain metabolism in Alzheimer's disease signature regions). The first group was amyloid-positive and neurodegeneration-positive, which corresponds to stage 2 of preclinical Alzheimer's disease. The second group was amyloid-positive and neurodegeneration-negative, which corresponds to stage 1 of preclinical Alzheimer's disease. The third group was amyloid-negative and neurodegeneration-positive, which corresponds to 'suspected non-Alzheimer's pathophysiology'. The last group was the control group, defined by amyloid-negative and neurodegeneration-negative subjects. We analysed 314 baseline 256-channel high-density eyes closed 1-min resting state EEG recordings. EEG biomarkers included spectral measures, algorithmic complexity and functional connectivity assessed with a novel information-theoretic measure, weighted symbolic mutual information. The most prominent effects of neurodegeneration on EEG metrics were localized in frontocentral regions with an increase in high frequency oscillations (higher beta and gamma power) and a decrease in low frequency oscillations (lower delta power), higher spectral entropy, higher complexity and increased functional connectivity measured by weighted symbolic mutual information in theta band. Neurodegeneration was associated with a widespread increase of median spectral frequency. We found a non-linear relationship between amyloid burden and EEG metrics in neurodegeneration-positive subjects, either following a U-shape curve for delta power or an inverted U-shape curve for the other metrics, meaning that EEG patterns are modulated differently depending on the degree of amyloid burden. This finding suggests initial compensatory mechanisms that are overwhelmed for the highest amyloid load. Together, these results indicate that EEG metrics are useful biomarkers for the preclinical stage of Alzheimer's disease.
Disciplines :
Neurology
Author, co-author :
Gaubert, Sinead ✱
Raimondo, Federico ✱; Université de Liège - ULiège > Consciousness-Coma Science Group
✱ These authors have contributed equally to this work.
Language :
English
Title :
EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
Publication date :
2019
Journal title :
Brain: a Journal of Neurology
ISSN :
0006-8950
eISSN :
1460-2156
Publisher :
Oxford University Press, Oxford, United Kingdom
Volume :
142
Issue :
7
Pages :
2096-2112
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 2009; 12: 1567-76.
Allen EA, Erhardt EB, Damaraju E, Gruner W, Segall JM, Silva RF, et al. A baseline for the multivariate comparison of resting-state networks. Front Syst Neurosci 2011; 5: 2.
Al-Nuaimi AHH, Jammeh E, Sun L, Ifeachor E. Complexity measures for quantifying changes in electroencephalogram in Alzheimer's disease. Complexity 2018; 2018: 1-12.
Babiloni C, Binetti G, Cassetta E, Forno GD, Percio CD, Ferreri F, et al. Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clin Neurophysiol 2006; 117: 252-68.
Babiloni C, Frisoni G, Pievani M, Vecchio F, Lizio R, Buttiglione M, et al. Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. NeuroImage 2009; 44: 123-35.
Babiloni C, Lizio R, Marzano N, Capotosto P, Soricelli A, Triggiani AI, et al. Brain neural synchronization and functional coupling in Alzheimer's disease as revealed by resting state EEG rhythms. Int J Psychophysiol 2016; 103: 88-102.
Babiloni C, Visser PJ, Frisoni G, De Deyn PP, Bresciani L, Jelic V, et al. Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiol Aging 2010; 31: 1787-98.
Bassett SS, Yousem DM, Cristinzio C, Kusevic I, Yassa MA, Caffo BS, et al. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain 2006; 129: 1229-39.
Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-44.
Blinowska KJ, Rakowski F, Kaminski M, De Vico Fallani F, Del Percio C, Lizio R, et al. Functional and effective brain connectivity for discrimination between Alzheimer's patients and healthy individuals: a study on resting state EEG rhythms. Clin Neurophysiol 2017; 128: 667-80.
Bluhm RL, Osuch EA, Lanius RA, Boksman K, Neufeld RWJ, Théberge J, et al. Default mode network connectivity: effects of age, sex, and analytic approach: Neuroreport 2008; 19: 887-91.
Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol 2016; 15: 1044-53.
Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K-H, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008; 321: 1686-9.
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015; 84: 508-15.
Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al. Basal cerebral metabolism may modulate the cognitive effects of A in mild cognitive impairment: an example of brain reserve. J Neurosci 2009; 29: 14770-8.
de Haan W, Mott K, van Straaten ECW, Scheltens P, Stam CJ. Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. PLoS Comput Biol 2012; 8: e1002582.
de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-71.
Dottori M, Sedeño L, Martorell Caro M, Alifano F, Hesse E, Mikulan E, et al. Towards affordable biomarkers of frontotemporal dementia: a classification study via network's information sharing. Sci Rep 2017; 7: 3822.
Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-13.
Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol 2018; 17: 335-46.
Engemann D, Raimondo F, King J-R, Jas M, Gramfort A, Dehaene S. Automated measurement and prediction of consciousness in vegetative and minimally conscious patients. In: ICML Workshop on Statistics, Machine Learning and Neuroscience 2015, Lille, France, 2015.
Engemann DA, Raimondo F, King J-R, Rohaut B, Louppe G, Faugeras F, et al. Robust EEG-based cross-site and cross-protocol classification of states of consciousness. Brain J Neurol 2018; 141: 3179-92.
Filbey FM, Slack KJ, Sunderland TP, Cohen RM. Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEϵ4 in young healthy adults. Neuroreport 2006; 17: 1585-90.
Filippi M, Valsasina P, Misci P, Falini A, Comi G, Rocca MA. The organization of intrinsic brain activity differs between genders: a resting-state fMRI study in a large cohort of young healthy subjects. Hum Brain Mapp 2013; 34: 1330-43.
Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease: neuronal Loss in the Superior Temporal Sulcus in Alzheimer's Disease. Ann Neurol 1997; 41: 17-24.
Gramfort A, Luessi M, Larson E, Engemann DA, Strohmeier D, Brodbeck C, et al. MEG and EEG data analysis with MNE-Python. Front Neurosci 2013; 7: 267.
Grunwald M, Busse F, Hensel A, Kruggel F, Riedel-Heller S, Wolf H, et al. Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia. J Clin Neurophysiol 2001; 18: 178-84.
Habert M-O, Bertin H, Labit M, Diallo M, Marie S, Martineau K, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Ann Nucl Med 2018; 32: 75-86.
Hornero R, Abasolo D, Escudero J, Gomez C. Nonlinear analysis of electroencephalogram and magnetoencephalogram recordings in patients with Alzheimer's disease. Philos Trans R Soc Math Phys Eng Sci 2009; 367: 317-36.
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14: 535-62.
Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765-75.
Jagust W. Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain 2016; 139: 23-30.
Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006; 59: 673-81.
Jelic V, Johansson SE, Almkvist O, Shigeta M, Julin P, Nordberg A, et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging 2000; 21: 533-40.
Jeong J. EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol 2004; 115: 1490-505.
Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, et al. Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging 2014; 35: 576-84.
Jones DT, Graff-Radford J, Lowe VJ, Wiste HJ, Gunter JL, Senjem ML, et al. Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex 2017; 97: 143-59.
Jones DT, Knopman DS, Gunter JL, Graff-Radford J, Vemuri P, Boeve BF, et al. Cascading network failure across the Alzheimer's disease spectrum. Brain 2016; 139: 547-62.
King J-R, Sitt JD, Faugeras F, Rohaut B, El Karoui I, Cohen L, et al. Information sharing in the brain indexes consciousness in noncommunicative patients. Curr Biol 2013; 23: 1914-9.
Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly: neuronal injury biomarkers. Ann Neurol 2013; 73: 472-80.
Kramer G, van der Flier WM, de Langen C, Blankenstein MA, Scheltens P, Stam CJ. EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. Clin Neurophysiol 2008; 119: 2727-32.
Lim HK, Nebes R, Snitz B, Cohen A, Mathis C, Price J, et al. Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain 2014; 137: 3327-38.
Lind J, Persson J, Ingvar M, Larsson A, Cruts M, Van Broeckhoven C, et al. Reduced functional brain activity response in cognitively intact apolipoprotein E ϵ4 carriers. Brain 2006; 129: 1240-8.
Luckhaus C, Grass-Kapanke B, Blaeser I, Ihl R, Supprian T, Winterer G, et al. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study. Int J Geriatr Psychiatry 2008; 23: 1148-55.
Melloni M, Sedeño L, Hesse E, García-Cordero I, Mikulan E, Plastino A, et al. Cortical dynamics and subcortical signatures of motor-language coupling in Parkinson's disease. Sci Rep 2015; 5: 11899.
Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014; 71: 1379.
Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex 2011; 21: 2399-407.
Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-31.
Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 2010; 20: 843-54.
Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009; 36: 811-22.
Nakamura A, Cuesta P, Fernández A, Arahata Y, Iwata K, Kuratsubo I, et al. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. Brain 2018; 141: 1470-85.
Nakamura A, Cuesta P, Kato T, Arahata Y, Iwata K, Yamagishi M, et al. Early functional network alterations in asymptomatic elders at risk for Alzheimer's disease. Sci Rep 2017; 7: 6517.
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-81.
Palop JJ, Mucke L. Amyloid-b-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010; 13: 812-8.
Sitt JD, King J-R, El Karoui I, Rohaut B, Faugeras F, Gramfort A, et al. Large scale screening of neural signatures of consciousness in patients in a vegetative or minimally conscious state. Brain 2014; 137: 2258-70.
Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. NeuroImage 2009; 44: 83-98.
Soldan A, Pettigrew C, Cai Q, Wang M-C, Moghekar AR, O'Brien RJ, et al. Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol 2016; 73: 698.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J Neurol Sci 2010; 289: 128-34.
Stam CJ, van der Made Y, Pijnenburg YAL, Scheltens P. EEG synchronization in mild cognitive impairment and Alzheimer's disease. Acta Neurol Scand 2003; 108: 90-6.
Staudinger T, Polikar R. Analysis of complexity based EEG features for the diagnosis of Alzheimer's disease. Conf Proc IEEE Eng Med Biol Soc. 2011; 2011: 2033-6.
Stomrud E, Hansson O, Minthon L, Blennow K, Rosen I, Londos E. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiol Aging 2010; 31: 215-23.
Teipel S, Bakardjian H, Gonzalez-Escamilla G, Cavedo E, Weschke S, Dyrba M, et al. No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. Neuroimage Clin 2018; 17: 435-43.
Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2014; 2: 26.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957-65.
Weissman-Fogel I, Moayedi M, Taylor KS, Pope G, Davis KD. Cognitive and default-mode resting state networks: do male and female brains 'rest' differently? Hum Brain Mapp 2010; 31: 1713-26.
Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013; 70: 1512-9.
